Upcoming first-line chemotherapy for HER2-negative gastric cancer in Japan: which patients benefit from immunotherapy?

被引：4
|
作者：
Takahari, Daisuke [1 ]
Chin, Keisho [1 ]
Yamaguchi, Kensei [1 ]
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Tokyo, Japan
来源：
FUTURE ONCOLOGY | 2020年 / 16卷 / 24期
关键词：
first-line chemotherapy; gastric cancer; pembrolizumab monotherapy; TAS-118 plus oxaliplatin; SOL; DOUBLE-BLIND; PHASE-III; CISPLATIN; NIVOLUMAB; S-1;
D O I：
10.2217/fon-2020-0421
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1797 / 1799
页数：3
相关论文
共 50 条
  • [31] Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial
    Verschoor, Noortje
    Bos, Manouk K.
    de Kruijff, Ingeborg E.
    Van, Mai N.
    Kraan, Jaco
    Drooger, Jan C.
    Zuetenhorst, Johanna M.
    Wilting, Saskia M.
    Sleijfer, Stefan
    Jager, Agnes
    Martens, John W. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 205 (01) : 87 - 95
  • [32] First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study
    Qin, Shukui
    Bai, Yuxian
    Li, Jin
    Pan, Hongming
    Luo, Suxia
    Qu, Yanli
    Ye, Feng
    Yang, Lin
    Liu, Tianshu
    Li, Wei
    Chen, Xi
    Yang, Jianwei
    Ying, Jieer
    Lin, Xiaoyan
    Zhao, Lin
    Liang, Xinjun
    Mao, Yixiang
    Guo, Run
    Zuo, Yi
    Bordia, Sonal
    Li, Shouguo
    ADVANCES IN THERAPY, 2025, : 1892 - 1906
  • [33] Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status
    Goncalves, Anthony
    Deblock, Mathilde
    Esterni, Benjamin
    Tarpin, Carole
    Bertucci, Francois
    Gilabert, Marine
    Charafe-Jauffret, Emmanuelle
    Jacquemier, Jocelyne
    Houvenaeghel, Gilles
    Extra, Jean-Marc
    Viens, Patrice
    ANTI-CANCER DRUGS, 2009, 20 (10) : 946 - 952
  • [34] Reply to: Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer
    Goldhirsch, A.
    Coates, A. S.
    ANNALS OF ONCOLOGY, 2014, 25 (03) : 755 - 755
  • [35] Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
    Yuan Yang
    Zhang Shaohua
    Wang Tao
    Bian Li
    Yan Min
    Yin Yongmei
    Song Yuhua
    Wen Yi
    Li Jianbin
    Jiang Zefei
    中华医学杂志英文版, 2023, 136 (12)
  • [36] Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
    Yuan, Yang
    Zhang, Shaohua
    Wang, Tao
    Bian, Li
    Yan, Min
    Yin, Yongmei
    Song, Yuhua
    Wen, Yi
    Li, Jianbin
    Jiang, Zefei
    CHINESE MEDICAL JOURNAL, 2023, 136 (12) : 1459 - 1467
  • [37] Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis
    Bonotto, Marta
    Gerratana, Lorenzo
    Di Maio, Massimo
    De Angelis, Carmine
    Cinausero, Marika
    Moroso, Stefano
    Milano, Monica
    Stanzione, Brigida
    Gargiulo, Piera
    Iacono, Donatella
    Minisini, Alessandro Marco
    Mansutti, Mauro
    Fasola, Gianpiero
    De Placido, Sabino
    Arpino, Grazia
    Puglisi, Fabio
    BREAST, 2017, 31 : 114 - 120
  • [38] Immune checkpoint inhibitors combined with paclitaxel-based chemotherapy versus chemotherapy alone as first-line treatment in HER2-negative advanced gastric cancer: result of a multicenter retrospective study
    Fang, Yulu
    Zhao, Yifan
    Yu, Xiaofu
    Liu, Shuxun
    Tao, Gang
    Zhong, Haijun
    Xiang, Hai
    Yang, Yunshan
    Shi, Zhong
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (02) : 585 - 596
  • [39] A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer
    Puglisi, Fabio
    Bisagni, Giancarlo
    Ciccarese, Mariangela
    Fontanella, Caterina
    Gamucci, Teresa
    Leo, Luigi
    Molino, Annamaria
    Silva, Rosa Rita
    Marchetti, Paolo
    FUTURE ONCOLOGY, 2016, 12 (22) : 2589 - 2602
  • [40] First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study
    Dieras, Veronique
    Pop, Simona
    Berger, Frederique
    Dujaric, Marie-Eglantine
    Beuzeboc, Philippe
    Escalup, Laurence
    Bidard, Francois Clement
    Cottu, Paul Henri
    Le Tourneau, Christophe
    Piperno-Neumann, Sophie
    Laurence, Valerie
    Robain, Mathieu
    Asselain, Bernard
    Pierga, Jean-Yves
    ANTICANCER RESEARCH, 2017, 37 (03) : 1403 - 1407
12345